Thorough QT study to evaluate the effect of amifampridine on cardiac repolarisation in healthy volunteers

Trial Profile

Thorough QT study to evaluate the effect of amifampridine on cardiac repolarisation in healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 31 May 2016

At a glance

  • Drugs Amifampridine (Primary)
  • Indications Lambert-Eaton myasthenic syndrome
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Apr 2014 New trial record
    • 08 Jan 2014 Primary endpoint 'QT-interval' has been met, according to Catalyst Pharmaceutical Partners media release.
    • 08 Jan 2014 Positive safety results reported in Catalyst Pharmaceutical Partners media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top